In 2014, Elizabeth Holmes was everywhere.
She graced the cover of Forbes, sat on panels with Bill Clinton and Henry Kissinger, and promised a device the size of a credit card could run hundreds of medical tests from a single finger prick.
Her company, Theranos, was valued at $9 billion.
The pitch was irresistible in Silicon Valley's mythology: a Stanford dropout in a black turtleneck, voice deliberately lowered, dropping out at 19 to disrupt the lab industry.
She said her technology could do more with less blood than traditional labs, faster and cheaper.
Walgreens signed a deal to put the devices in its stores.
The problem was that the technology didn't work.
According to reporting that later won a Pulitzer Prize, Theranos was secretly running most of its tests on commercially available machines — the same ones it claimed to replace.
Employees who raised concerns were pushed out.
The company stayed private for years, which meant its internal failures escaped the scrutiny that public companies face.
In October 2015, Wall Street Journal reporter John Carreyrou published a series of articles pulling the curtain back.
Theranos pushed back hard, threatening legal action against critics.
In 2016, federal inspectors found the company's California lab posed "immediate jeopardy to patient health and safety." Theranos voided two years of test results — tens of thousands of them.
By 2018, the company was dissolved and Holmes had been charged with wire fraud.
The trial became a cultural event in 2021, with Holmes testifying that her former partner and COO, Ramesh "Sunny" Balwani, had abused her and controlled much of her behavior.
In January 2022, a jury found Holmes guilty on four counts of fraud.
She was sentenced to 11 years and three months in federal prison, later reduced slightly for good behavior.
She reported to a Texas prison camp in May 2023.
A book, a documentary, and a limited series all retold the same strange arc: the world's youngest self-made female billionaire, undone by her own blood tests.
What makes the Holmes story stick isn't the fraud itself — scams are ancient.
It's that so many smart people wanted to believe.
Investors, journalists, board members including George Shultz and Henry Kissinger, and a media ecosystem hungry for a female Steve Jobs all overlooked what lab scientists spotted quickly.
The myth was more useful than the evidence.
The closing takeaway here is uncomfortable.
The Theranos collapse wasn't just one liar's failure — it was an entire ecosystem's failure to ask basic questions when the story was too good.
Final Thoughts
The next Elizabeth Holmes is probably already pitching someone right now, and the turtleneck may look different.